Antibody Therapeutics San Francisco Xchange 2026

Biointron is pleased to announce our participation in Antibody Therapeutics Xchange – San Francisco 2026, taking place September 2, 2026, in San Francisco, California. 

Hosted by hubXchange, Antibody Therapeutics Xchange brings together senior-level scientists and executives from the pharmaceutical and biotech sectors for a focused, discussion-led meeting on key challenges in antibody therapeutic development. The 2026 San Francisco program will cover topics including target selection and mechanisms of action, lead identification and optimization, antibody formats and scaffolds, bi/multispecifics, ADC linker design and conjugation technologies, and ADC cytotoxic payloads. 

The event reflects the continued expansion of antibody therapeutics beyond conventional monoclonal antibodies, with growing interest in complex modalities such as bispecific and multispecific antibodies, ADCs, engineered scaffolds, and optimized lead-generation strategies. These advances are increasing the need for robust antibody engineering, expression, characterization, and developability support throughout the discovery pipeline. 

Biointron looks forward to joining the antibody therapeutics community in San Francisco and connecting with researchers, developers, and industry partners working to advance the next generation of antibody-based medicines. 

For more details about the event, please visit the Antibody Therapeutics San Francisco Xchange 2026 website [https://hub-xchange.com/xchanges/antibody-therapeutics-xchange-san-francisco-2026] 

Time: September 2, 2026 

Location: DoubleTree by Hilton Hotel San Francisco Airport | San Francisco, CA